Longitudinal risk of cutaneous squamous cell carcinoma development following PD-1 inhibitor therapy for melanoma: A

Related Experiment Video

Updated: Jan 8, 2026

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

6.1K

Faria Nusrat1, Kyle Lauck2, Tara Jennings2

  • 1Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania; Cooper Center for Dermatologic Surgery, Cooper University Hospital, Evesham, New Jersey.

Journal of the American Academy of Dermatology
|December 13, 2025
PubMed
Abstract

No abstract available in PubMed .

Keywords:
PD-1 inhibitorscutaneous squamous cell carcinomametastatic melanomanivolumabpembrolizumabrelative risk

More Related Videos

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.3K
A Melanoma Patient-Derived Xenograft Model07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

13.1K

Related Concept Videos

Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
13.1K